HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rune R Frants Selected Research

voltage-dependent calcium channel (P-Q type)

3/2014RNA expression profiling in brains of familial hemiplegic migraine type 1 knock-in mice.
3/2012Purkinje cell-specific ablation of Cav2.1 channels is sufficient to cause cerebellar ataxia in mice.
9/2010Severe and progressive neurotransmitter release aberrations in familial hemiplegic migraine type 1 Cacna1a S218L knock-in mice.
7/2010Quantitative cortical synapse proteomics of a transgenic migraine mouse model with mutated Ca(V)2.1 calcium channels.
1/2010High cortical spreading depression susceptibility and migraine-associated symptoms in Ca(v)2.1 S218L mice.
10/2008Premature stop codons in a facilitating EF-hand splice variant of CaV2.1 cause episodic ataxia type 2.
4/2007Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacna1a-mutant mouse rolling Nagoya.
12/2006Conditional inactivation of the Cacna1a gene in transgenic mice.
3/2004A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rune R Frants Research Topics

Disease

14Migraine Disorders (Migraine)
03/2014 - 06/2002
9Migraine with Aura (Familial Hemiplegic Migraine)
03/2014 - 09/2003
4Epilepsy (Aura)
03/2013 - 03/2004
4Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy)
08/2010 - 06/2005
3Muscular Dystrophies (Muscular Dystrophy)
05/2013 - 11/2010
3Metabolic Syndrome (Dysmetabolic Syndrome X)
04/2010 - 04/2005
3Ataxia (Dyssynergia)
01/2009 - 12/2006
2Cerebellar Ataxia (Dysmetria)
03/2014 - 03/2012
2Dysferlinopathy
05/2013 - 06/2005
2Dystonia (Limb Dystonia)
03/2012 - 12/2006
2Insulin Resistance
04/2010 - 03/2010
2Obesity
04/2010 - 03/2010
2Headache (Headaches)
01/2010 - 05/2007
2Hyperlipidemias (Hyperlipidemia)
05/2009 - 10/2005
2Muscular Diseases (Myopathy)
03/2007 - 06/2005
2Inflammation (Inflammations)
10/2006 - 12/2005
2Pathologic Constriction (Stenosis)
12/2005 - 07/2004
2Hyperekplexia
07/2002 - 07/2002
1Leukoencephalopathies
11/2016
1Disease Progression
05/2013
1variable Immunodeficiency syndrome
06/2011
1Type 2 Diabetes Mellitus (MODY)
02/2010
1Hyperlipoproteinemia Type III (Broad Beta Disease)
05/2009
1Episodic Ataxia
01/2009
1Seizures (Absence Seizure)
01/2009
1Alternating hemiplegia of childhood
01/2009
1Migraine without Aura (Common Migraine)
11/2008
1Type 2 Episodic Ataxia
10/2008
1Limb-girdle muscular dystrophy type 2A
06/2008
1Thrombosis (Thrombus)
12/2007
12 Combined Hyperlipidemia
10/2007
1Atherosclerosis
10/2007
1Hypertriglyceridemia
10/2007
1Brain Diseases (Brain Disorder)
05/2007
1Muscle Weakness
04/2007
1Lambert-Eaton Myasthenic Syndrome (Lambert-Eaton Syndrome)
04/2007
1Miyoshi myopathy
03/2007
1Neointima
01/2007
1Nervous System Diseases (Neurological Disorders)
12/2006
1Disease Susceptibility (Diathesis)
07/2006
1Stroke (Strokes)
02/2006
1Coronary Disease (Coronary Heart Disease)
09/2005

Drug/Important Bio-Agent (IBA)

9voltage-dependent calcium channel (P-Q type)IBA
03/2014 - 03/2004
5DysferlinIBA
05/2013 - 06/2005
4Pharmaceutical PreparationsIBA
01/2010 - 01/2005
3Calcium Channels (Calcium Channel)IBA
07/2010 - 06/2002
3Adenosine Triphosphatases (ATPase)IBA
08/2007 - 09/2003
2HDL CholesterolIBA
03/2013 - 04/2010
2Neurotransmitter Agents (Neurotransmitter)IBA
09/2010 - 07/2009
2CalpainIBA
08/2010 - 06/2008
2Triglycerides (Triacylglycerol)IBA
04/2010 - 10/2007
2AdiponectinIBA
04/2010 - 02/2010
2Glucose (Dextrose)FDA LinkGeneric
04/2010 - 03/2010
2Insulin (Novolin)FDA Link
04/2010 - 03/2010
2Fatty Acids (Saturated Fatty Acids)IBA
03/2010 - 10/2007
2Biomarkers (Surrogate Marker)IBA
07/2009 - 07/2006
2PotassiumIBA
11/2008 - 06/2004
2Glycine Receptors (Glycine Receptor)IBA
07/2002 - 07/2002
1Retinaldehyde (Retinal)IBA
11/2016
1RNA (Ribonucleic Acid)IBA
03/2014
1IntegrinsIBA
05/2013
1Fibronectins (Fibronectin)IBA
05/2013
1Transcription Factors (Transcription Factor)IBA
04/2013
1SmokeIBA
03/2013
1DNA-Binding Proteins (DNA Binding Protein)IBA
06/2011
1Cysteine Proteases (Cysteine Protease)IBA
08/2010
1Hormones (Hormone)IBA
04/2010
1C-Reactive ProteinIBA
04/2010
1Dietary Fats (Dietary Fat)IBA
03/2010
1StearatesIBA
03/2010
1Folic Acid (Vitamin M)FDA LinkGeneric
07/2009
1EnzymesIBA
07/2009
1Oxidoreductases (Dehydrogenase)IBA
07/2009
1Apolipoprotein E2IBA
05/2009
1ApolipoproteinsIBA
05/2009
1Glutamic Acid (Glutamate)FDA Link
01/2009
1Amino Acid Transport System X-AG (Glutamate Transporter)IBA
01/2009
1IonsIBA
11/2008
1Nonsense Codon (Nonsense Mutation)IBA
10/2008
1EmulsionsIBA
10/2007
1CholesterolIBA
10/2007
1Ion Channels (Ion Channel)IBA
05/2007
15-HT1B Serotonin ReceptorIBA
05/2007
1Sodium Channels (Sodium Channel)IBA
05/2007
1Sumatriptan (Imigran)FDA LinkGeneric
05/2007
1DNA (Deoxyribonucleic Acid)IBA
05/2007
1AutoantibodiesIBA
04/2007
1Estrogen Receptor alphaIBA
01/2007
1pyrazoleIBA
01/2007
1Phenol (Carbolic Acid)FDA Link
01/2007
1NAD (NADH)IBA
01/2007
1Estrogen Receptor betaIBA
01/2007
1HomocysteineIBA
02/2006
1Messenger RNA (mRNA)IBA
12/2005
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2005
1Thalidomide (Thalomid)FDA Link
12/2005
1LipidsIBA
10/2005

Therapy/Procedure

4Percutaneous Coronary Intervention
12/2007 - 04/2005
3Stents
01/2007 - 07/2004
2Therapeutics
05/2007 - 04/2005